Wyeth to restructure sales group

In a new sign of the drug industry's changing views of how it handles drug sales, Wyeth is planning to eliminate or switch to part-time status about 30% of its drug reps, according to a report in the Wall Street Journal. Some companies have been rethinking their strategy of "mirroring" sales efforts by sending multiple reps to the same physician to tout the same drug. The practice has swelled the number of drug reps past the 100,000 mark, and alienated many physicians in the process. Wyeth's move will affect about 750 workers.

- read this story from AFX for more

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.